# An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer

> **NCT07685041** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** HS-10504； midazolam

## Key facts

- **NCT ID:** NCT07685041
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-27
- **Primary completion:** 2026-11-19
- **Final completion:** 2027-07-20
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685041, "An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07685041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*